{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Revvity, Inc. Hits 52-Week Low at USD 81.23 Amid Declining Sales
Revvity, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low, reflecting a significant decline in stock performance over the past year. The company faces challenges in profitability, with decreasing net sales and operating profit, while its market capitalization is approximately USD 9,668 million.
Revvity, Inc. Experiences Valuation Adjustment Amidst Competitive Market Landscape
Revvity, Inc., a small-cap firm in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation metrics, including a P/E ratio of 34 and a price-to-book value of 1.33. The company has faced stock performance challenges, with a year-to-date return of -11.96%, contrasting with the S&P 500's gain.
Revvity, Inc. Hits Day Low at $82.86 Amid Price Pressure
Revvity, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, saw its stock price decline significantly today. The firm has struggled financially, with a year-long return of -10.91% and ongoing decreases in net sales and operating profit, raising concerns about its profitability and market position.
Revvity, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Challenges
Revvity, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has experienced notable stock fluctuations and mixed technical indicators. Its performance has lagged behind the S&P 500, with negative returns year-to-date and over the past year, suggesting challenges in aligning with broader market trends.
Revvity, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Indicators
Revvity, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has seen its stock price decline recently. The company has struggled over the past year, with significant drops compared to the S&P 500, indicating ongoing challenges in a competitive market environment.
Revvity, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics
Revvity, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has experienced a challenging year with a return of -13.99%. The stock has shown volatility, with a 52-week range between 81.36 and 120.39, while recent trading activity reflects fluctuations in its performance metrics.
Revvity, Inc. Faces Valuation Shift Amid Declining Sales and Rising Costs
Revvity, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has recently experienced a change in its valuation grade. Key financial metrics reveal challenges, including a decline in net sales and operating profit, alongside rising raw material costs and a high debt-equity ratio, impacting its market position.
Is Revvity, Inc. overvalued or undervalued?
As of October 31, 2025, Revvity, Inc. is considered very expensive and overvalued with a P/E ratio of 33 and an EV to EBITDA of 15.29, significantly underperforming the S&P 500 with a year-to-date return of -17.85%.
Is Revvity, Inc. overvalued or undervalued?
As of October 31, 2025, Revvity, Inc. is considered very expensive and overvalued with a P/E ratio of 33, underperforming the S&P 500 significantly, as evidenced by its year-to-date return of -16.70% compared to the index's 16.30%.
Is Revvity, Inc. overvalued or undervalued?
As of October 31, 2025, Revvity, Inc. is considered overvalued with a valuation grade of very expensive, reflected by high financial metrics and underperformance against the S&P 500.
Is Revvity, Inc. overvalued or undervalued?
As of October 31, 2025, Revvity, Inc. is considered overvalued with a P/E ratio of 33 and has underperformed the S&P 500, raising concerns about its stock price relative to earnings growth prospects.
Is Revvity, Inc. overvalued or undervalued?
As of October 17, 2025, Revvity, Inc. is considered very expensive with a P/E ratio of 33 and has underperformed the S&P 500 with a year-to-date return of -16.30%.
Revvity, Inc. Experiences Valuation Adjustment Amidst Competitive Market Landscape
Revvity, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has experienced a valuation adjustment, with a current P/E ratio of 33. Its performance has been mixed, showing a year-to-date return of -16.30% and a decline of 21.53% over the past year, contrasting with the S&P 500's gains.
Is Revvity, Inc. overvalued or undervalued?
As of October 17, 2025, Revvity, Inc. is considered very expensive and overvalued due to its high P/E ratio of 33 compared to peers, a PEG ratio of 3.05 indicating growth isn't justifying its price, and low returns on equity and capital, despite short-term outperformance against the S&P 500.
Is Revvity, Inc. overvalued or undervalued?
As of October 17, 2025, Revvity, Inc. is considered very expensive with a P/E ratio of 33 and has underperformed the S&P 500, indicating it may be overvalued compared to its peers.
Revvity, Inc. Experiences Evaluation Revision Amid Mixed Market Signals and Performance Challenges
Revvity, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has seen its stock price decline recently amid a challenging year, marked by a 24.67% drop. Technical indicators present mixed signals, reflecting a complex market environment as Revvity's performance diverges significantly from the S&P 500.
Is Revvity, Inc. technically bullish or bearish?
As of October 3, 2025, Revvity, Inc. shows a mildly bearish trend with mixed technical signals, having outperformed the S&P 500 recently but underperformed year-to-date.
Is Revvity, Inc. technically bullish or bearish?
As of October 3, 2025, Revvity, Inc. shows a mildly bearish trend with mixed technical signals, underperforming the S&P 500 with year-to-date and one-year returns of -15.73% and -24.21%, respectively.
Is Revvity, Inc. technically bullish or bearish?
As of October 3, 2025, Revvity, Inc. shows a mildly bearish trend with mixed technical signals, underperforming the S&P 500 with a year-to-date return of -15.73% compared to the S&P's 14.18%.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
